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The TRAPP vesicle-tethering complex consists of more than 10 distinct polypeptides and is involved
in protein transport. Using the C2 subunit as bait we identiﬁed SPATA4, a spermatocyte-speciﬁc pro-
tein of unknown function, as an interacting partner in a yeast two hybrid screen. Further studies
indicate SPATA4 interacts with the C2 portion of the TRAPP complex. SPATA4 fractionates with both
cytosolic and nuclear fractions suggesting it may have several distinct functions. SPATA4 is one of
only three human proteins that contain a DUF1042 domain and we show that C2 does not interact
with another one of the DUF1042 domain-containing proteins. Our results suggest a role for SPATA4
in membrane trafﬁc and a specialized function for TRAPP in spermatocytes.
Structured summary of protein interactions:
C2 physically interacts with SPATA4 by two hybrid (View Interaction 1, 2)
C2 physically interacts with POSTN by two hybrid (View interaction)
C2L physically interacts with REPS2 by two hybrid (View interaction)
C2L physically interacts with TRAPPC3 by two hybrid (View interaction)
C2 physically interacts with LAP3 by two hybrid (View interaction)
C2 physically interacts with SPATA4 by anti bait coimmunoprecipitation (View interaction)
C2L physically interacts with SPATA22 by two hybrid (View interaction)
SPATA4, C2 and C3 colocalize by cosedimentation through density gradient (View interaction)
SPATA4 binds to C2 by pull down (View interaction)
C2 physically interacts with TRAPPC3 by two hybrid (View interaction)
C2L physically interacts with SPATA4 by anti tag coimmunoprecipitation (View interaction)
C2 physically interacts with REPS2 by two hybrid (View interaction)
SPATA4 and C2 physically interact by molecular sieving (View interaction)
C2L physically interacts with LAP3 by two hybrid (View interaction)
C2 physically interacts with SPATA22 by two hybrid (View interaction)
C2L physically interacts with POSTN by two hybrid (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The process of vesicle-mediated delivery of both membranes
and proteins to their proper intracellular location requires many
factors acting in a coordinated manner. Many unanswered ques-
tions remain with respect to the molecular mechanisms regulating
these processes.
The complexes that tether these vesicles to the acceptor com-
partment have been well-studied at the structural level [1]. Onechemical Societies. Published by E
rsity, Department of Biology,
ada H4B 1R6.
acher).
d are listed alphabetically.such complex called TRAPP functions in the early portion of the
secretory pathway leading to transport to the Golgi [2]. TRAPP or
subunits within the complex have been proposed to carry out
numerous functions including vesicle tethering [3,4], nucleotide
exchange for several small GTPases [5–8], regulation of gene
expression [9,10] and to contribute to Golgi morphology [8,11].
To fulﬁll all of these functions, the complex interacts with speciﬁc
vesicle coat proteins, GTPases, transcription factors and likely other
proteins. Curiously, a mutation in one subunit called TRAPPC2
(henceforth called C2) has been tied to a skeletal defect called
spondyloepiphyseal dysplasia tarda (SEDT) [12]. Interestingly,
while most SEDT patients have mutations that lead to a truncated
C2 protein, one patient with a D47Y missense mutation was iden-
tiﬁed. Since this mutation is in a region of the protein that to datelsevier B.V. All rights reserved.
Table 1
C2 interactors identiﬁed in yeast two-hybrid screen.
Interactor cDNA accession
number
LAP3 – leucine aminopeptidase 3 NM_015907.2
REPS2 – RALBP1 associated Eps domain containing 2 NM_001980975.1
POSTN – periostin, osteoblast speciﬁc factor NM_006475.1
SPATA22 – spermatogenesis associated 22 NM_032598.3
SPATA4 – spermatogenesis associated 4 NM_144644.2
TRAPPC3 – trafﬁcking protein particle complex 3 NM_014408.3
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was suggested that it may interfere with an interaction between
TRAPP and an as yet unidentiﬁed binding partner [13].
To better understand the regulation of TRAPP, we decided to
look for proteins that interact with C2. Using a yeast two-hybrid
screen, we show that a spermatocyte-speciﬁc protein of unknown
function called SPATA4 binds speciﬁcally to this subunit. SPATA4
binds to the C2 portion of TRAPP and co-fractionates with the high
molecular weight pool of C2. Ectopically expressed SPATA4 dis-
plays a cytosolic and nuclear localization. Our data suggest a role
for SPATA4 in membrane trafﬁc in spermatocytes and imply a spe-
cialized function for the TRAPP complex in these cells.
2. Materials and methods
A detailed materials and methods can be found in the Supple-
mentary data.
2.1. Yeast two hybrid screen
The yeast two hybrid screen was performed as described in the
Matchmaker™ Pretransformed Libraries User Manual (Clontech).
The identity of positive clones was performed by polymerase chain
reaction using the oligonucleotides pGAD-F-ID and pGAD-R-ID (Ta-
ble S1) followed by sequence analysis. Plasmids used in this study
are listed in Table S2.
2.2. Co-immunoprecipitation and gel ﬁltration
Samples for co-immunoprecipitation (CoIP) contained 1 mg of
lysate in phosphate buffered saline and 2 lg of IgG. For Western
analysis, primary antibodies used were mouse anti-myc (Upstate)
and mouse anti-FLAG (Sigma). Secondary antibody used was
peroxidase-labelled goat anti-mouse IgG (Kirkegaard & Perry
Laboratories).
2.3. Recombinant protein preparation
Cells were grown at 37 C and protein production was in-
duced by the addition of IPTG. Cells were collected by centrifu-
gation and resuspended in the appropriate column buffer for
maltose binding protein (MBP) fusion proteins, glutathione-S-
transferase (GST) fusion proteins or polyhistidine (His)-tagged
proteins.
Puriﬁcation of MBP fusion protein using amylose resin (New
England Biolabs), GST fusion protein using glutathione sepharose
beads (GE Healthcare) and His-tagged protein using Ni2+-NTA Aga-
rose (Qiagen) were as per the manufacturer’s instructions.
2.4. In vitro binding assay
In vitro binding assays contained 0.1–0.5 lM of either MBP or
MBP-SPATA4 with increasing amounts (0–0.5 lM) of either sub-
complexes composed of C2/His-C3/C5 or His-C3/C5, His-C2 or a
peptide comprising the two C-terminal helices of C2 (H2/H3 C2)
fused to GST. Samples were treated with amylose resin, washed
and detected by western analysis using afﬁnity puriﬁed polyclonal
antibody recognizing C2 or anti-GST (Sigma).
2.5. Fluorescence microscopy
Cells were ﬁxed 48 h after transfection in cold methanol or 4%
paraformaldehyde. The cells were visualized on a Zeiss Axioplan
Fluorescence microscope using a 63 oil EC Plan-Neoﬂuar objec-
tive. Images were overlayed using Adobe Photoshop.2.6. Live cell imaging
Cells were visualized either 24 or 48 h post-transfection. Images
were captured on a Leica DMI6000 B inverted microscope coupled
with a Hamamatsu C10600 ORCA-R2 digital camera.
2.7. Cellular fractionation
Cytosolic and nuclear fractionation were performed as previ-
ously described [14] except that sucrose was added to buffer N
after homogenization of the cells. For western blot analysis, equal
volumes of the normalized fractions were analyzed.
3. Results
3.1. Identiﬁcation of SPATA4 as a C2 binding partner
To begin to understand the regulation of the function of TRAPP,
we undertook a yeast two-hybrid (Y2H) screen using C2 as the bait.
A normalized, human cDNA library in prey plasmids, produced
from multiple tissues, was used in the screen. After the initial
screen, >180 potential interactors were identiﬁed. Potential inter-
actors were narrowed down by all of the following methods: (i)
duplicates were identiﬁed by colony PCR and AluI restriction anal-
ysis; (ii) plasmids were rescued and tested for autoactivation; (iii)
plasmids were re-tested to remove false-positives. This process left
6 potential interactors (Table 1) including the C3 subunit of TRAPP
which was previously shown to directly interact with C2 [13].
The six interactors were tested for speciﬁcity by checking their
ability to interact with the TRAPP subunit C2L which is closely re-
lated to C2 [11]. Only SPATA4 discriminated in its ability to bind to
C2 and C2L while the remaining interactors bound to both proteins
(Fig. 1). For this reason, we chose to focus the remainder of this
study on SPATA4.
SPATA4 is a highly conserved protein that has been found in
numerous species [15–19]. Human SPATA4 is 305 residues in
length and contains a DUF1042 domain of unknown function. Se-
quence analysis of the cDNA clone isolated in our screen revealed
a frameshift that resulted in a 38 amino acid truncation of the pro-
tein from the carboxy-terminus suggesting that this region is not
important for its interaction with C2 (see below).
3.2. C2 and SPATA4 interact in vivo
To conﬁrm the Y2H results, we examined the ability of C2 and
SPATA4 to interact in vivo. As shown in Fig. 2A, FLAG-SPATA4 co-
precipitated with myc-C2 (lane 4). We noted that the levels of
FLAG-SPATA4 were considerably higher when the protein was
co-expressed with myc-C2 compared to when it was expressed
in its absence (compare lanes 1 and 2). This result was seen numer-
ous times, however the basis for it remains unclear. Although an
interaction between SPATA4 and C2L was not detected by Y2H
(see above), we found that myc-C2L could also precipitate
Fig. 1. SPATA4 interacts with C2 by yeast two-hybrid. Yeast cells harboring C2 or
C2L in the bait plasmid pGBKT7, or an empty bait plasmid (vector) and the prey
plasmid pGADT7 with the inserts indicated (see Table 1) were grown on medium
lacking tryptophan and leucine, lacking tryptophan, leucine and histidine with
1 mM 3-amino-1,2,4-triazol (3-AT), or lacking tryptophan, leucine, histidine and
adenine with X-a-Gal. SPATA4 interacted speciﬁcally with C2 and not C2L under the
two experimental conditions tested.
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is precipitating TRAPP which contains C2 [11]. FLAG-SPATA4 did
not co-precipitate with myc-ECT2, a protein unrelated to C2 used
as a negative control. Identical results were obtained when anti-
FLAG was used as the precipitating antibody. These results conﬁrm
the Y2H interaction and suggest that SPATA4 interacts with TRAPP.
3.3. SPATA4 binds to the TRAPP complex
To further conﬁrm the interaction between SPATA4 and C2 we
performed an in vitro binding assay using MBP-SPATA4 and
His6-C2. As shown in Fig. 3A, we were unable to detect binding
between these proteins above background levels in this system.
When the binding assay was performed using a heterotrimeric
form of C2 bound to its neighboring subunits (C2/His-C3/C5Fig. 2. SPATA4 and C2 interact in vivo. Lysates were prepared from HEK293T cells co-tr
lanes 2 and 5: FLAG-SPATA4 with pRK5MYC; lanes 3 and 6: pFLAGCMV6a with myc-C2
myc-C2L; (C) lanes 1 and 3: FLAG-SPATA4 with myc-ECT2 (amino acids 421–883); lan
immunoprecipitated (co-IP) with rabbit anti-C2 (A) or rabbit anti-myc (B, C). Precipitatesheterotrimer) efﬁcient binding was readily seen (Fig. 3B). It is note-
worthy that the binding to the heterotrimeric complex was sufﬁ-
ciently strong that the levels of MBP-SPATA4 were reduced
ﬁvefold and the levels of the C2/His-C3/C5 were reduced twofold
in the assay compared to monomeric C2. An interaction between
glutathione-S-transferase (GST)-tagged C2L and MBP-SPATA4
could not be detected (not shown). Interestingly, when just a het-
erodimer of His-C3/C5 was used, binding of MBP-SPATA4 could be
readily detected (Fig. 3C). These results suggest that SPATA4 pref-
erentially interacts with the C2-localized portion of TRAPP and also
recognizes a region on the C3/C5 dimer.
Consistent with the above notion, lysates fractionated by size
exclusion chromatography showed that FLAG-SPATA4 was found
in a high molecular weight fraction that also contained TRAPP-
associated C2 (Fig. 3D). Signiﬁcantly, there was no pool of SPATA4
even in fractions that contained non-TRAPP-associated C2. This
fractionation was not affected by co-expression of myc-C2 (not
shown) except that the levels of SPATA4 were greater when the
two proteins were co-expressed as stated above. This high molec-
ular weight pool of FLAG-SPATA4 coimmunoprecipitated with sev-
eral TRAPP proteins (Fig. 3E). Collectively, our results suggest that
SPATA4 binds to the TRAPP complex through the C2-containing
end.
3.4. Deﬁning the regions of interaction between SPATA4 and C2
Since SPATA4 was identiﬁed through its interaction with C2, we
sought to determine which regions of SPATA4 and C2 mediate the
interaction between the proteins. Although largely similar, the
three-dimensional crystal structure of C2 as part of the heterotri-
meric complex differs slightly from uncomplexed C2 [13,20]. Spe-
ciﬁcally, helix 1 is extended in the heterotrimeric complex by
incorporating additional residues on both the amino- and car-
boxy-terminal sides. We used several C2 mutants to determine
whether SPATA4 interacts with this helix. First, the amino-terminal
91 residues of C2 containing helix 1 (spanning residues 31–54 in
C2 in the heterotrimeric complex) was cloned into the bait vector
and tested for an interaction with SPATA4. As demonstrated inansfected with plasmids expressing: (A) lanes 1 and 4: FLAG-SPATA4 with myc-C2;
; (B) lanes 1 and 3: FLAG-SPATA4 with myc-C2L; lanes 2 and 4: pFLAGCMV6a with
es 2 and 4: pFLAGCMV6a with myc-ECT2 (amino acids 421–883). Samples were
were analyzed by western blotting using mouse anti-myc and mouse anti-FLAG IgG.
Fig. 3. SPATA4 binds to TRAPP. MBP or MBP-SPATA4 were subjected to an in vitro binding assay as described in Section 2 using amylose resin to pull down MBP and MBP-
SPATA4 with increasing amounts of either His-C2 (A), C2/His-C3/C5 (B) or His-C3/C5 (C). Samples were probed by western blotting using anti-C2 (A, B) or anti-C3 (C) IgG. (D)
Lysates were prepared from HEK293T cells transfected with a plasmid expressing FLAG-SPATA4 or myc-C2. Lysates were fractionated on a Superdex™ 200 column and
fractions were analyzed by western blotting using anti-myc and anti-FLAG antibodies. (E) FLAG-SPATA4 fractions from (D) were untreated (lane 1) or immunoprecipitated
with anti-C2 (lane 2), anti-C3 (lane 3) or anti-C11 (lane 4) IgG and probed with anti-FLAG IgG. (F) Full length C2 or the indicated fragments and mutants were tested for an
interaction with SPATA4 by yeast two hybrid. Serial dilutions were spotted on medium lacking either leucine and tryptophan, leucine, tryptophan and histidine with 3-AT, or
leucine, tryptophan, histidine and adenine. (G) MBP or MBP-SPATA4 were subjected to an in vitro binding assay as in (A) with increasing amounts of GST fused to residues 91–
140 of C2 (helices 2 and 3; GST-C2(H2/H3)). Samples were probed by western blotting using anti-GST IgG. (H) SPATA4 constructs were tested for interaction with C2 by yeast
two hybrid (see Supplementary Fig. 1). The SPATA4 fragments generated are (human numbering): M1 (1–212), M2 (55–212), M3 (55–162), M4 (163–212) and M5 (1–162).
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highly conserved additional residues (31–34 and 51–55) that are
incorporated into helix 1 in the heterotrimeric form of C2 into
alanines. All of these mutant forms of C2 retained their ability to
interact with SPATA4 (Fig. 3F). Finally, we found that the patho-
genic D47Y SEDT mutation in helix 1 of C2 had no effect on binding
to SPATA4 (Fig. 3F). These results argue against a role for the
involvement of helix 1 of C2 with SPATA4. We then focused our
attention to the carboxy-terminal portion of C2 which contains
two antiparallel helices called helix 2 and helix 3 (H2/H3) which
were deleted in the amino-terminal construct described above.
As shown in Fig. 3G, GST-tagged recombinant H2/H3 (residues
91–140) was indeed able to bind MBP-SPATA4. Consistent with
these results, a construct lacking the ﬁnal 17 residues of C2 that
represent H3 failed to interact with SPATA4 (Fig. 3F). These results
suggest that the carboxy-terminal helix of C2 is necessary for
interaction with SPATA4.
To deﬁne the portion of SPATA4 that interacts with C2 we
cloned portions of the protein into the prey vector and tested their
ability to bind to C2 by Y2H. As shown in Fig. 3H and Figure S1,
deletion of the entire carboxy-terminal portion of the protein untilthe DUF1042 domain did not affect its interaction with C2. Further
truncations into the DUF1042 domain ablated the interaction
suggesting that this domain is required for the interaction with
C2. However, the DUF1042 domain (amino acids 55–212) alone
was unable to bind to C2. When SPEF1, one of two other
DUF1042-containing proteins, was tested for binding to C2, no
interaction was detected (not shown). These results suggest that
the DUF1042 domain of SPATA4 is necessary but not sufﬁcient
for its interaction with C2.
3.5. SPATA4 is found in both the cytosol and in the nucleus
The binding of SPATA4 to TRAPP suggests that SPATA4 should
be found in the cytosol. We tested this notion by cell fractionation
and ﬂuorescence microscopy using green ﬂuorescent protein
(GFP)-tagged SPATA4. Upon fractionation, a portion of GFP-SPATA4
was indeed found in the cytosol (Fig. 4A). A signiﬁcant portion was
also found in the nuclear-enriched fraction consistent with an
earlier study [18]. The latter result was not due to cross-contami-
nation between the nuclear and cytosolic fractions since the
cytosolic marker (b-COP) and two TRAPP subunits, C2 and C3, were
Fig. 4. Localization of SPATA4 in HEK293T cells. (A) HEK293T cells were transfected with pGFP-SPATA4 and harvested 48 h later. The cells were lysed and separated into
cytosolic (C) and nuclear fractions (N). Aliquots were analyzed by western blotting using anti-GFP, anti-C2, anti-C3, anti-histone B (nuclear marker) and anti-b-COP (cytosolic
marker). (B) HEK293T cells were transfected with pGFP-SPATA4 and visualized after ﬁxation with either paraformaldehyde (top row) or methanol (middle row). The bottom
panel shows a representative image of unﬁxed, live cells. Cytosolic localization is not due to background ﬂuorescence since there are a number of untransfected, non-
ﬂuorescent cells in the ﬁelds as demonstrated by the DAPI merge for the methanol ﬁxed samples and the DIC merge of the live cells. The scale bars represent 20 lm.
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supports the interaction between C2 and SPATA4 taking place in
the cytosol.
We then sought to conﬁrm the biochemical fractionation by
ﬂuorescence microscopic localization of GFP-SPATA4. When cells
were visualized after ﬁxing with 4% paraformaldehyde, GFP-SPAT-
A4 displayed a nuclear localization in 89.4% of the cells (n = 47)
(Fig. 4B). Curiously, when cells were ﬁxed with methanol, the
localization of GFP-SPATA4 was cytosolic in 89.4% of the cells
(n = 104) with some cells displaying punctae (Fig. 4B). As neither
of these results were consistent with the biochemical fractionation
we visualized GFP-SPATA4 in live cells where no ﬁxation method is
used. In this case, all of the transfected cells showed the GFP-SPAT-
A4 signal in both the nucleus and the cytosol (Fig. 4B). Although
some cells showed a stronger signal in one of these compartments,
the GFP-SPATA4 signal in those cells could also be seen in the other
compartment. Although it remains to be shown whether
GFP-SPATA4 is functional, the localization seen in live cells
suggests that GFP-SPATA4 localization is dynamic.
4. Discussion
We present evidence that SPATA4, a protein of unknown func-
tion, interacts speciﬁcally with a protein involved in membrane
trafﬁc. Collectively, our data implicate SPATA4 in a role in
membrane trafﬁc by virtue of its association with the TRAPP
complex. It is noteworthy that a low molecular weight pool of
SPATA4, similar to that of C2 with which it interacts, was not
detected. Rather, all of the ectopically expressed, cytosolic SPATA4
co-fractionated with TRAPP. The fact that SPATA4 is expressed
almost exclusively in spermatocytes, suggests that TRAPP may
perform a function speciﬁc to these cells. Although subcellular
fractionation suggested that a portion of SPATA4 was found in
the nucleus, this pool of SPATA4 would not be seen in our gel ﬁltra-
tion fractions since the protocol removes nuclei and DNA from the
sample prior to size-exclusion chromatography. Given a previous
report that C2 is found in the nucleus [21], we cannot rule out aSPATA4–C2 interaction taking place in this compartment. It should
be noted, however, that the previous report was based on the
fractionation of overexpressed C2 while our fractionation focused
on the endogenous protein. In addition, our in vitro binding assay
argues against a SPATA4 interaction with non-TRAPP-associated
C2. Although SPATA4 was identiﬁed in a yeast two hybrid screen
using C2 as the bait, SPATA4 bound more efﬁciently in vitro to
His-C3/C5 compared to His-C2. It is possible that the yeast two
hybrid interaction may have been mediated by a mixed TRAPP
complex composed of human C2 with yeast TRAPP proteins. Such
a complex is likely produced in yeast since the human protein
complements its yeast ortholog [11,22]. Alternatively, the interac-
tion in vivo is more stable than that in vitro.
A recent study suggests that SPATA4 is localized to the cytosol
in the osteoblast cell line MC3T3-E1 where it interacts with and
promotes the phosphorylation of the kinase ERK1 [23]. An earlier
study reported the localization of GFP-SPATA4 to the nucleus
[18]. Our present work shows GFP-SPATA4 localizing to and
fractionating with both the cytosol and nucleus in live cells.
Clearly, this is a dynamic protein with perhaps several functions.
Interestingly, mutations in C2 that lead to the skeletal defect SEDT
include carboxy-terminal truncations [24], a region we have de-
ﬁned as important for the interaction with SPATA4. The position
of C2 within TRAPP and its interactions with neighbouring
subunits leave available this carboxy-terminal helix for interac-
tions with non-stably-associated members of the complex [13]. It
remains to be seen whether ablation of the SPATA4–C2 interaction
in the cytosol is a contributing factor to SEDT.
A previous study on ectopically expressed SPATA4 in MCF7 cells
showed that it increased their growth rate by allowing the cells to
progress through S phase more rapidly [17]. While the mechanism
for the increased growth rate of these cells is unclear, our present
study suggests it may be due to a more active secretory pathway.
The involvement of the DUF1042 domain in binding to C2 is
interesting in light of the fact that this domain has been implicated
in microtubule interactions [25]. Given that ER-derived carriers
migrate along microtubule tracks [26], it is tempting to speculate
D.T. Duarte et al. / FEBS Letters 585 (2011) 2676–2681 2681that SPATA4 may link TRAPP to the microtubule network to facili-
tate membrane trafﬁc in spermatocytes. Alternatively, profound
changes to the cytoskeletal microtubule network accompany divi-
sion of spermatocytes and development of spermatids [27]. Such
changes may present special needs for membrane trafﬁc and SPAT-
A4 would be well positioned to allow this vesicle tether to adapt to
the changing cytoskeletal landscape. In addition, given the link be-
tween SPATA4 and ERK1, it is tempting to speculate that this pro-
tein of unknown function serves to link TRAPP to ERK1 and thus
allow membrane trafﬁc to respond to signaling events as previ-
ously suggested [28]. Clearly, further studies on the SPATA4 pro-
tein in an appropriate spermatocyte model system are needed to
further elucidate the function of this TRAPP-interacting protein.
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